Daniel O'Day, CEO
Roche has announced plans to acquire the ROS1/TRK inhibitor entrectinib, through an all-cash .7 billion-dollar merger with Ignyta. Roche will pay .00 per share for Ignyta, representing a 71% premium. The transaction was approved by both companies and Roche has begun acquiring outstanding shares. The transaction is expected to close in early 2018.
Several studies continue to enroll patients to investigate entrectinib. Based on communications with the FDA, Ignyta, which plans to continue operating out of San Diego, anticipates submission of a new drug application for the treatment in 2018.
- Ahn M-J, Cho BC, Siena S, et al. Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). Presented at: IASLC 18th World Conference on Lung Cancer; October 15-18, 2017; Yokohama, Japan. Abstract 8564.
- Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400-409.
... to read the full story